Literature DB >> 12778774

[Atherosclerosis and uremia: signifance of non-traditional risk factors].

Walter H Hörl1.   

Abstract

Arteriosclerosis, atherosclerosis and vascular calcification are causally related to the high morbidity and mortality of patients with chronic renal failure. Oxidative stress and carbonyl stress of uremia, dialysis procedure and/or intravenous iron therapy result in AGE (advanced glycation end-product), ALE (advanced lipoxidation end-product) and AOPP (advanced oxidation protein product) formation, favouring together with elevated CRP (C-reactive protein) levels the development of cardiovascular and cerebrovascular complications. Enhanced plasma levels of homocysteine and ADMA (asymmetric dimethylarginine) contribute to this process. In addition, in chronic renal insufficiency hyperphosphatemia and an enhanced calcium x phosphorus ion product are associated with the morbidity and mortality of the patients, particularly in the presence of fetuin deficiency. Phosphorus, AGEs and AOPPs, beside other factors, catalyze the conversion of vascular smooth muscle cells to osteoblast--like cells (particularly in the presence of monocytes/macrophages), resulting in bone matrix protein formation. Other risk factors, such as age, male sex, smoking, hypertension, diabetes, chronic inflammation, insulin resistance or dyslipidemia (enhanced non-HDL-cholesterol) also contribute to the atherosclerotic risk profile of the patient with chronic renal insufficiency. While there is growing understanding of the mechanisms involved in arteriosclerosis, atherosclerosis and vascular calcification in uremia, we are still missing effective therapeutic maneuvers for reduction of excess mortality in uremic patients.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12778774     DOI: 10.1007/bf03040320

Source DB:  PubMed          Journal:  Wien Klin Wochenschr        ISSN: 0043-5325            Impact factor:   1.704


  177 in total

1.  Plasma homocysteine, aortic stiffness, and renal function in hypertensive patients.

Authors:  L A Bortolotto; M E Safar; E Billaud; C Lacroix; R Asmar; G M London; J Blacher
Journal:  Hypertension       Date:  1999-10       Impact factor: 10.190

Review 2.  Progression of vascular calcification in uraemic patients: can it be stopped?

Authors:  Tilman B Drüeke; Stephen G Rostand
Journal:  Nephrol Dial Transplant       Date:  2002-08       Impact factor: 5.992

3.  Asymmetric dimethylarginine, C-reactive protein, and carotid intima-media thickness in end-stage renal disease.

Authors:  Carmine Zoccali; Francesco Antonio Benedetto; Renke Maas; Francesca Mallamaci; Giovanni Tripepi; Lorenzo Salvatore Malatino; Rainer Böger
Journal:  J Am Soc Nephrol       Date:  2002-02       Impact factor: 10.121

4.  Oral folate enhances endothelial function in hyperhomocysteinaemic subjects.

Authors:  M F Bellamy; I F McDowell; M W Ramsey; M Brownlee; R G Newcombe; M J Lewis
Journal:  Eur J Clin Invest       Date:  1999-08       Impact factor: 4.686

5.  Evidence for a link between glycoxidation and lipoperoxidation in patients with chronic renal failure.

Authors:  J Meng; N Sakata; Y Imanaga; Y Tachikawa; J Chihara; S Takebayashi
Journal:  Clin Nephrol       Date:  1999-05       Impact factor: 0.975

Review 6.  Homocysteine and cardiovascular disease: cause or effect?

Authors:  L Brattström; D E Wilcken
Journal:  Am J Clin Nutr       Date:  2000-08       Impact factor: 7.045

7.  Phosphate regulation of vascular smooth muscle cell calcification.

Authors:  S Jono; M D McKee; C E Murry; A Shioi; Y Nishizawa; K Mori; H Morii; C M Giachelli
Journal:  Circ Res       Date:  2000-09-29       Impact factor: 17.367

Review 8.  Advanced glycation end products: a Nephrologist's perspective.

Authors:  D S Raj; D Choudhury; T C Welbourne; M Levi
Journal:  Am J Kidney Dis       Date:  2000-03       Impact factor: 8.860

9.  Riboflavin is a determinant of total homocysteine plasma concentrations in end-stage renal disease patients.

Authors:  Sonja Skoupy; Manuela Födinger; Mario Veitl; Agnes Perschl; Heidi Puttinger; Claudia Röhrer; Karin Schindler; Andreas Vychytil; Walter H Hörl; Gere Sunder-Plassmann
Journal:  J Am Soc Nephrol       Date:  2002-05       Impact factor: 10.121

10.  Polymorphism in methylenetetrahydrofolate reductase gene: its impact on plasma homocysteine levels and carotid atherosclerosis in ESRD patients receiving hemodialysis.

Authors:  P S Lim; W R Hung; Y H Wei
Journal:  Nephron       Date:  2001-03       Impact factor: 2.847

View more
  2 in total

1.  [Remission of chronic kidney diseases. A realistic goal?].

Authors:  Gert Mayer
Journal:  Wien Klin Wochenschr       Date:  2003-07-15       Impact factor: 1.704

2.  Relation of asymmetric dimethylarginine levels to macrovascular disease and inflammation markers in type 2 diabetic patients.

Authors:  Mustafa Celik; Serkan Cerrah; Mahmut Arabul; Aysen Akalin
Journal:  J Diabetes Res       Date:  2014-04-03       Impact factor: 4.011

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.